CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows

A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses.

≈